Abstract
A significant amount of research has been focused on the relationship between hormones and Alzheimers disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimers disease. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum luteinizing hormone concentrations. Indeed, there is growing evidence that the gonadotropin, luteinizing hormone, which regulates serum estrogen and testosterone concentrations, could be an important causative factor in the development of Alzheimers disease. This review provides information supporting the "gonadotropin hypothesis, " puts forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of Alzheimers disease, and discusses potential therapeutic anti-gonadotropin compounds.
Keywords: Luteinizing hormone (LH), follicle-stimulating hormone (FSH), Alzheimer's disease, gonadotropin releasing hormone (GnRH), cell cycle, estrogen
Current Pharmaceutical Design
Title: Antigonadotropins: A Novel Strategy to Halt Alzheimers Disease Progression
Volume: 12 Issue: 6
Author(s): Christopher W. Gregory, Craig S. Atwood, Mark A. Smith and Richard L. Bowen
Affiliation:
Keywords: Luteinizing hormone (LH), follicle-stimulating hormone (FSH), Alzheimer's disease, gonadotropin releasing hormone (GnRH), cell cycle, estrogen
Abstract: A significant amount of research has been focused on the relationship between hormones and Alzheimers disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimers disease. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum luteinizing hormone concentrations. Indeed, there is growing evidence that the gonadotropin, luteinizing hormone, which regulates serum estrogen and testosterone concentrations, could be an important causative factor in the development of Alzheimers disease. This review provides information supporting the "gonadotropin hypothesis, " puts forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of Alzheimers disease, and discusses potential therapeutic anti-gonadotropin compounds.
Export Options
About this article
Cite this article as:
Gregory W. Christopher, Atwood S. Craig, Smith A. Mark and Bowen L. Richard, Antigonadotropins: A Novel Strategy to Halt Alzheimers Disease Progression, Current Pharmaceutical Design 2006; 12 (6) . https://dx.doi.org/10.2174/138161206775474288
DOI https://dx.doi.org/10.2174/138161206775474288 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Current Pharmaceutical Design Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Role of Histone Acetylation in Cell Cycle Regulation
Current Topics in Medicinal Chemistry Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in Cancer
Current Topics in Medicinal Chemistry Toxicity of Magnetic Resonance Imaging Agents: Small Molecule and Nanoparticle
Current Topics in Medicinal Chemistry Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis
Current Genomics Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment
Current Pharmaceutical Design Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
Current Radiopharmaceuticals Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Current Medicinal Chemistry Src Inhibitors and Angiogenesis
Current Pharmaceutical Design Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Give Boron a Chance: Boron Containing Compounds Reach Ionotropic and Metabotropic Transmembrane Receptors
Mini-Reviews in Medicinal Chemistry Hetero-Oligomerization of Chemokine Receptors: Diversity and Relevance for Function
Current Medicinal Chemistry An Evidence-Based Review of Medicinal Plants in the Overall Management of Chronic Fatigue
Current Psychiatry Research and Reviews Radiofrequency Radiation and Human Triiodothronine Hormone: Immunoenzymometric Assay
Recent Patents on Biomarkers Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer
Mini-Reviews in Medicinal Chemistry Meet the Editorial Board
Combinatorial Chemistry & High Throughput Screening Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy